144 related articles for article (PubMed ID: 12935959)
1. FLT3-activating mutations in acute promyelocytic leukaemia: a rationale for risk-adapted therapy with FLT3 inhibitors.
Gilliland DG
Best Pract Res Clin Haematol; 2003 Sep; 16(3):409-17. PubMed ID: 12935959
[TBL] [Abstract][Full Text] [Related]
2. A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657.
Sohal J; Phan VT; Chan PV; Davis EM; Patel B; Kelly LM; Abrams TJ; O'Farrell AM; Gilliland DG; Le Beau MM; Kogan SC
Blood; 2003 Apr; 101(8):3188-97. PubMed ID: 12515727
[TBL] [Abstract][Full Text] [Related]
3. Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group.
Callens C; Chevret S; Cayuela JM; Cassinat B; Raffoux E; de Botton S; Thomas X; Guerci A; Fegueux N; Pigneux A; Stoppa AM; Lamy T; Rigal-Huguet F; Vekhoff A; Meyer-Monard S; Ferrand A; Sanz M; Chomienne C; Fenaux P; Dombret H;
Leukemia; 2005 Jul; 19(7):1153-60. PubMed ID: 15889156
[TBL] [Abstract][Full Text] [Related]
4. Transcription therapy for acute promyelocytic leukaemia.
Douer D
Expert Opin Investig Drugs; 2000 Feb; 9(2):329-46. PubMed ID: 11060680
[TBL] [Abstract][Full Text] [Related]
5. PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model.
Kelly LM; Kutok JL; Williams IR; Boulton CL; Amaral SM; Curley DP; Ley TJ; Gilliland DG
Proc Natl Acad Sci U S A; 2002 Jun; 99(12):8283-8. PubMed ID: 12060771
[TBL] [Abstract][Full Text] [Related]
6. PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy.
Cicconi L; Divona M; Ciardi C; Ottone T; Ferrantini A; Lavorgna S; Alfonso V; Paoloni F; Piciocchi A; Avvisati G; Ferrara F; Di Bona E; Albano F; Breccia M; Cerqui E; Sborgia M; Kropp MG; Santoro A; Levis A; Sica S; Amadori S; Voso MT; Mandelli F; Lo-Coco F
Leukemia; 2016 Oct; 30(10):1987-1992. PubMed ID: 27133819
[TBL] [Abstract][Full Text] [Related]
7. Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study.
Lucena-Araujo AR; Kim HT; Jacomo RH; Melo RA; Bittencourt R; Pasquini R; Pagnano K; Fagundes EM; Chauffaille Mde L; Chiattone CS; Lima AS; Ruiz-Argüelles G; Undurraga MS; Martinez L; Kwaan HC; Gallagher R; Niemeyer CM; Schrier SL; Tallman MS; Grimwade D; Ganser A; Berliner N; Ribeiro RC; Lo-Coco F; Löwenberg B; Sanz MA; Rego EM
Ann Hematol; 2014 Dec; 93(12):2001-10. PubMed ID: 24981688
[TBL] [Abstract][Full Text] [Related]
8. Internal tandem duplication and Asp835 mutations of the FMS-like tyrosine kinase 3 (FLT3) gene in acute promyelocytic leukemia.
Shih LY; Kuo MC; Liang DC; Huang CF; Lin TL; Wu JH; Wang PN; Dunn P; Lai CL
Cancer; 2003 Sep; 98(6):1206-16. PubMed ID: 12973844
[TBL] [Abstract][Full Text] [Related]
9.
Esnault C; Rahmé R; Rice KL; Berthier C; Gaillard C; Quentin S; Maubert AL; Kogan S; de Thé H
Blood; 2019 Mar; 133(13):1495-1506. PubMed ID: 30674471
[TBL] [Abstract][Full Text] [Related]
10. FLT3-TKD mutation in childhood acute myeloid leukemia.
Liang DC; Shih LY; Hung IJ; Yang CP; Chen SH; Jaing TH; Liu HC; Wang LY; Chang WH
Leukemia; 2003 May; 17(5):883-6. PubMed ID: 12750701
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic intervention in leukemias that express the activated fms-like tyrosine kinase 3 (FLT3): opportunities and challenges.
Sternberg DW; Licht JD
Curr Opin Hematol; 2005 Jan; 12(1):7-13. PubMed ID: 15604885
[TBL] [Abstract][Full Text] [Related]
12. Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol.
Noguera NI; Breccia M; Divona M; Diverio D; Costa V; De Santis S; Avvisati G; Pinazzi MB; Petti MC; Mandelli F; Lo Coco F
Leukemia; 2002 Nov; 16(11):2185-9. PubMed ID: 12399960
[TBL] [Abstract][Full Text] [Related]
13. FLT3 and its role in the pathogenesis of acute myeloid leukaemia.
Reilly JT
Leuk Lymphoma; 2003 Jan; 44(1):1-7. PubMed ID: 12691136
[TBL] [Abstract][Full Text] [Related]
14. Cytogenetic and FMS-like tyrosine kinase 3 mutation analyses in acute promyelocytic leukemia patients.
Yaghmaie M; Alimoghaddam K; Mozdarani H; Ghavamzadeh A; Hajhashemi M; Aznab M; Ghaffari SH
Iran Biomed J; 2012; 16(1):10-7. PubMed ID: 22562027
[TBL] [Abstract][Full Text] [Related]
15. Targeting FLT3 kinase in acute myelogenous leukemia: progress, perils, and prospects.
Heinrich MC
Mini Rev Med Chem; 2004 Mar; 4(3):255-71. PubMed ID: 15032673
[TBL] [Abstract][Full Text] [Related]
16. FLT3 internal tandem duplication in childhood acute myeloid leukaemia: association with hyperleucocytosis in acute promyelocytic leukaemia.
Arrigoni P; Beretta C; Silvestri D; Rossi V; Rizzari C; Valsecchi MG; Cazzaniga G; Biondi A
Br J Haematol; 2003 Jan; 120(1):89-92. PubMed ID: 12492581
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients.
Testa U; Lo-Coco F
Ann Hematol; 2016 Apr; 95(5):673-80. PubMed ID: 26920716
[TBL] [Abstract][Full Text] [Related]
18. Immunophenotype distinction between acute promyelocytic leukaemia and CD15- CD34- HLA-DR- acute myeloid leukaemia with nucleophosmin mutations.
Ferrari A; Bussaglia E; Úbeda J; Facchini L; Aventin A; Sierra J; Nomdedéu JF
Hematol Oncol; 2012 Sep; 30(3):109-14. PubMed ID: 21812014
[TBL] [Abstract][Full Text] [Related]
19. Impact of FLT3 mutations and promyelocytic leukaemia-breakpoint on clinical characteristics and prognosis in acute promyelocytic leukaemia.
Kuchenbauer F; Schoch C; Kern W; Hiddemann W; Haferlach T; Schnittger S
Br J Haematol; 2005 Jul; 130(2):196-202. PubMed ID: 16029447
[TBL] [Abstract][Full Text] [Related]
20. Understanding the molecular pathogenesis of acute promyelocytic leukemia.
Lo-Coco F; Hasan SK
Best Pract Res Clin Haematol; 2014 Mar; 27(1):3-9. PubMed ID: 24907012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]